Principal Financial Group Inc Immuno Gen, Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$12.46 - $29.95 $1.78 Million - $4.28 Million	142,738 Added 14.5%	1,127,402 $33.4 Million
Q3 2023 Nov 02, 2023	SELL	$14.09 - $19.87 $45,397 - $64,021	-3,222 Reduced 0.33%	984,664 $15.6 Million
Q2 2023 Aug 07, 2023	BUY	$3.75 - $20.05 $3.49 Million - $18.7 Million	931,890 Added 1664.21%	987,886 $18.6 Million
Q1 2023 May 09, 2023	BUY	$3.67 - $4.92 $8,121 - $10,887	2,213 Added 4.11%	55,996 $215,000
Q4 2022 Feb 09, 2023	BUY	$4.55 - $6.31 $7,352 - $10,196	1,616 Added 3.1%	53,783 $266,000
Q3 2022 Nov 09, 2022	BUY	$4.48 - $6.47 $23,672 - $34,187	5,284 Added 11.27%	52,167 $249,000
Q2 2022 Aug 10, 2022	SELL	$3.15 - $5.76 $368,931 - $674,616	-117,121 Reduced 71.41%	46,883 $211,000
Q1 2022 May 09, 2022	SELL	$4.26 - $7.48 $235,735 - $413,920	-55,337 Reduced 25.23%	164,004 $781,000
Q4 2021 Feb 09, 2022	SELL	$4.75 - $7.5 $140,685 - $222,135	-29,618 Reduced 11.9%	219,341 $1.63 Million
Q3 2021 Nov 09, 2021	SELL	$5.02 - $6.59 $21,736 - $28,534	-4,330 Reduced 1.71%	248,959 $1.41 Million
Q2 2021 Aug 10, 2021	SELL	$5.79 - $8.6 $36,332 - $53,965	-6,275 Reduced 2.42%	253,289 $1.67 Million
Q1 2021 May 10, 2021	BUY	$6.5 - $10.53 $122,492 - $198,437	18,845 Added 7.83%	259,564 $2.1 Million
Q4 2020 Feb 08, 2021	SELL	$3.7 - $7.66 $150,878 - $312,359	-40,778 Reduced 14.49%	240,719 $1.55 Million
Q3 2020 Nov 06, 2020	BUY	$3.45 - $4.89 $349,133 - $494,858	101,198 Added 56.13%	281,497 $1.01 Million
Q2 2020 Aug 05, 2020	BUY	$3.32 - $5.34 $460,786 - $741,143	138,791 Added 334.37%	180,299 $830,000
Q1 2020 May 12, 2020	BUY	$2.12 - $6.8 $7,882 - $25,282	3,718 Added 9.84%	41,508 $141,000
Q4 2019 Feb 05, 2020	SELL	$2.25 - $5.8 $7,812 - $20,137	-3,472 Reduced 8.41%	37,790 $193,000
Q3 2019 Nov 13, 2019	BUY	$2.22 - $3.39 $8,487 - $12,959	3,823 Added 10.21%	41,262 $100,000
Q2 2019 Aug 12, 2019	SELL	$1.8 - $3.3 $138,493 - $253,905	-76,941 Reduced 67.27%	37,439 $82,000
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $498 - $1,223	207 Added 0.18%	114,380 $310,000
Q4 2018 Feb 14, 2019	BUY	$3.94 - $9.7 $14,562 - $35,851	3,696 Added 3.35%	114,173 $548,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $62,814 - $82,243	7,304 Added 7.08%	110,477 $1.05 Million
Q2 2018 Aug 13, 2018	BUY	$9.52 - $12.15 $152,043 - $194,047	15,971 Added 18.31%	103,173 $0
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $69,948 - $135,198	10,440 Added 13.6%	87,202 $918,000
Q4 2017 Feb 13, 2018	BUY	$5.07 - $7.92 $322,999 - $504,567	63,708 Added 488.03%	76,762 $492,000
Q3 2017 Nov 02, 2017	BUY	$5.4 - $8.47 $70,491 - $110,567	13,054	13,054 $100,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account